|Chemical and physical data|
|Molar mass||406.46 g·mol−1|
|3D model (JSmol)|
MK-4409 is an experimental drug which acts as a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC50 of 11 nM, and both analgesic and antiinflammatory effects in animal studies. It was studied for the treatment of neuropathic pain and progressed to early stage human clinical trials by 2009.
- Chobanian HR, Guo Y, Liu P, Chioda MD, Fung S, Lanza TJ, et al. (June 2014). "Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain". ACS Medicinal Chemistry Letters. 5 (6): 717–21. doi:10.1021/ml5001239. PMC 4060928. PMID 24944750.
- Merck (15 October 2009). "Merck Pipeline, Oct 2009" (PDF). Merck.
- "MK 4409". Adis Insight. Springer Nature Switzerland AG.